COR-1167 sodium

Table of contents

• What is COR-1167 sodium?
• How does COR-1167 sodium work?
• Which conditions is COR-1167 sodium studied for?
• How is COR-1167 sodium given?
• What do the clinical trials show?
• What side effects are known?

What is COR-1167 sodium?

COR-1167 sodium is an investigational substance that acts as a corticotrophin releasing factor 2 (CRF2) agonist. It is being developed as a potential treatment for worsening heart failure (WHF). No marketing authorisation is mentioned in the available registry data, so it remains an investigational medicine.^[1]

How does COR-1167 sodium work?

COR-1167 sodium is designed to stimulate the corticotrophin releasing factor 2 receptor. The trial is evaluating whether this action influences natriuresis, body weight, levels of N-terminal pro B-type natriuretic peptide (NT-proBNP), the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS), and Left Atrial Volume Index (LAVi).^[1] The provided supplementary source does not describe the mechanism of action of COR-1167 sodium.

Which conditions is COR-1167 sodium studied for?

• Worsening heart failure (WHF) — a condition in which heart failure symptoms become more severe and require additional treatment. The CRAFT-WHF study is evaluating COR-1167 sodium in this population.^[1]

How is COR-1167 sodium given?

COR-1167 sodium is given as a subcutaneous injection. In the registered trial, three doses of COR-1167 were to be administered once daily for 4 weeks, compared with a placebo solution for injection.^[1]

What do the clinical trials show?

One Phase 2 trial, the CRAFT-WHF study (NCT06815471), has been registered for COR-1167 sodium in worsening heart failure. The trial planned to enrol 300 participants. It is an interventional study with a parallel design comparing three doses of COR-1167 against placebo. The trial is currently suspended.^[1]

The primary endpoints are the individual assessments of the dose-effect relationship of COR-1167 on natriuresis, body weight, NT-proBNP, KCCQ-TSS and LAVi. The study was designed to administer the study drug subcutaneously once daily for 4 weeks.^[1]

What side effects are known?

No side effects for COR-1167 sodium are reported in the available trial registry data or the supplementary source. The supplementary source describes omega-3 fatty acid compounds and does not mention COR-1167 sodium.^[2]